Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R, Sylvester R, Tsitsa C, de Mulder PH, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, Vermeylen K, Stoter G. de Wit R, et al. Among authors: van oosterom at. Br J Cancer. 1997;75(3):432-5. doi: 10.1038/bjc.1997.71. Br J Cancer. 1997. PMID: 9020492 Free PMC article. Clinical Trial.
EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.
De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R. De Mulder PH, et al. Among authors: van oosterom at. Br J Cancer. 1995 Feb;71(2):371-5. doi: 10.1038/bjc.1995.75. Br J Cancer. 1995. PMID: 7841054 Free PMC article. Clinical Trial.
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group).
Jansen RL, Sylvester R, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, Keizer J, van Oosterom AT, Meyer S, Vendrik CP, et al. Jansen RL, et al. Among authors: van oosterom at. Eur J Cancer. 1991;27(6):695-8. doi: 10.1016/0277-5379(91)90168-d. Eur J Cancer. 1991. PMID: 1829907
Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.
Stoter G, Sylvester R, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, Jones WG, van Oosterom AT, Vendrik CP, Spaander P, de Pauw M. Stoter G, et al. Among authors: van oosterom at. Cancer Res. 1987 May 15;47(10):2714-8. Cancer Res. 1987. PMID: 2436756 Clinical Trial.
Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT. Bontenbal M, et al. Among authors: van oosterom at. Br J Cancer. 1998 Jun;77(12):2257-63. doi: 10.1038/bjc.1998.375. Br J Cancer. 1998. PMID: 9649142 Free PMC article. Clinical Trial.
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group. Fosså SD, et al. Among authors: van oosterom at. Br J Cancer. 2005 Nov 28;93(11):1209-14. doi: 10.1038/sj.bjc.6602830. Br J Cancer. 2005. PMID: 16251877 Free PMC article. Clinical Trial.
367 results